These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15316320)

  • 1. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease.
    Geller SA; Dubinsky MC; Poordad FF; Vasiliauskas EA; Cohen AH; Abreu MT; Tran T; Martin P; Vierling JM; Targan SR
    Am J Surg Pathol; 2004 Sep; 28(9):1204-11. PubMed ID: 15316320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease.
    Teml A; Schwab M; Hommes DW; Almer S; Lukas M; Feichtenschlager T; Florin T; Seiderer J; Petritsch W; Bokemeyer B; Kreisel W; Herrlinger KR; Knoflach P; Bonaz B; Klugmann T; Herfarth H; Pedarnig N; Reinisch W
    Wien Klin Wochenschr; 2007; 119(17-18):519-26. PubMed ID: 17943403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy.
    Shastri S; Dubinsky MC; Fred Poordad F; Vasiliauskas EA; Geller SA
    Arch Pathol Lab Med; 2004 Jan; 128(1):49-53. PubMed ID: 14692812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients.
    van Asseldonk DP; Simsek M; de Boer NKH; Jharap B; Bloemena E; den Hartog G; Westerveld DB; Becx MC; Russel MG; Lissenberg-Witte BI; van Nieuwkerk CM; Mulder CJJ; Verheij J; van Bodegraven AA
    Scand J Gastroenterol; 2019 Jun; 54(6):753-760. PubMed ID: 31203688
    [No Abstract]   [Full Text] [Related]  

  • 5. The Prevalence of Nodular Regenerative Hyperplasia in Inflammatory Bowel Disease Patients Treated with Thioguanine Is Not Associated with Clinically Significant Liver Disease.
    van Asseldonk DP; Jharap B; Verheij J; den Hartog G; Westerveld DB; Becx MC; Russel MG; Engels LG; de Jong DJ; Witte BI; Mulder CJ; van Nieuwkerk CM; Bloemena E; de Boer NK; van Bodegraven AA
    Inflamm Bowel Dis; 2016 Sep; 22(9):2112-20. PubMed ID: 27482972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?
    Gilissen LP; Derijks LJ; Driessen A; Bos LP; Hooymans PM; Stockbrügger RW; Engels LG
    Dig Liver Dis; 2007 Feb; 39(2):156-9. PubMed ID: 17188950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension.
    Ferlitsch A; Teml A; Reinisch W; Ulbrich G; Wrba F; Homoncik M; Gangl A; Peck-Radosavljevic M; Vogelsang H
    Am J Gastroenterol; 2007 Nov; 102(11):2495-503. PubMed ID: 17894846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nodular Regenerative Hyperplasia of the Liver in Patients with IBD Treated with Allopurinol-Thiopurine Combination Therapy.
    Seinen ML; van Asseldonk DP; de Boer NK; Bouma G; van Nieuwkerk CM; Mulder CJ; Bloemena E; van Bodegraven AA
    Inflamm Bowel Dis; 2017 Mar; 23(3):448-452. PubMed ID: 28151736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy.
    Musumba CO
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1025-37. PubMed ID: 24099468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party.
    de Boer NK; Reinisch W; Teml A; van Bodegraven AA; Schwab M; Lukas M; Ochsenkühn T; Petritsch W; Knoflach P; Almer S; van der Merwe SW; Herrlinger KR; Seiderer J; Vogelsang H; Mulder CJ;
    Digestion; 2006; 73(1):25-31. PubMed ID: 16493198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study.
    Pavlidis P; Ansari A; Duley J; Oancea I; Florin T
    Inflamm Bowel Dis; 2014 Dec; 20(12):2239-46. PubMed ID: 25230165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.
    Dubinsky MC; Vasiliauskas EA; Singh H; Abreu MT; Papadakis KA; Tran T; Martin P; Vierling JM; Geller SA; Targan SR; Poordad FF
    Gastroenterology; 2003 Aug; 125(2):298-303. PubMed ID: 12891528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.
    Derijks LJ; de Jong DJ; Gilissen LP; Engels LG; Hooymans PM; Jansen JB; Mulder CJ
    Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):63-7. PubMed ID: 12544696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients.
    de Boer NK; Zondervan PE; Gilissen LP; den Hartog G; Westerveld BD; Derijks LJ; Bloemena E; Engels LG; van Bodegraven AA; Mulder CJ
    Dig Liver Dis; 2008 Feb; 40(2):108-13. PubMed ID: 18083079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a role for thioguanine therapy in IBD in 2017 and beyond?
    Taylor KM; Ward MG; Blaker PA; Sparrow MP
    Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):473-486. PubMed ID: 28276819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients.
    Simsek M; Meijer B; Ramsoekh D; Bouma G; van der Wouden EJ; den Hartog B; de Vries AC; Hoentjen F; Dijkstra G; de Boer SY; Jansen JM; van der Meulen AE; Beukers R; Brink MA; Steinhauser T; Oldenburg B; Gilissen LP; Naber TH; Verhagen MA; de Boer NKH; Mulder CJJ;
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):568-570. PubMed ID: 29775790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.
    Bayoumy AB; van Liere ELSA; Simsek M; Warner B; Loganayagam A; Sanderson JD; Anderson S; Nolan J; de Boer NK; Mulder CJJ; Ansari A
    BMC Gastroenterol; 2020 Sep; 20(1):296. PubMed ID: 32917155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
    van Asseldonk DP; Seinen ML; de Boer NK; van Bodegraven AA; Mulder CJ
    J Crohns Colitis; 2012 Feb; 6(1):95-101. PubMed ID: 22261533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A histopathologic pattern of centrilobular hepatocyte injury suggests 6-mercaptopurine-induced hepatotoxicity in patients with inflammatory bowel disease.
    Masia R; Pratt DS; Misdraji J
    Arch Pathol Lab Med; 2012 Jun; 136(6):618-22. PubMed ID: 22646267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
    Dubinsky MC; Feldman EJ; Abreu MT; Targan SR; Vasiliauskas EA
    Am J Gastroenterol; 2003 May; 98(5):1058-63. PubMed ID: 12809828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.